|
Market Closed -
Nasdaq
02:30:00 15/01/2026 am IST
|
5-day change
|
1st Jan Change
|
|
754.14 USD
|
-0.63%
|
 |
-2.88%
|
-2.30%
|
|
14/01 |
Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs
|
MT
| |
13/01 |
Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating
|
MT
| |
13/01 |
Raymond James Adjusts PT on Regeneron Pharmaceuticals to $820 From $800, Keeps Outperform Rating
|
MT
| |
13/01 |
Regeneron Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02:15 PM
| | |
09/01 |
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $911 From $818, Maintains Outperform Rating
|
MT
| |
09/01 |
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,200,000, According to a Recent SEC Filing
|
MT
| |
08/01 |
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $914 From $807, Maintains Buy Rating
|
MT
| |
08/01 |
Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology
|
CI
| |
08/01 |
RBC Raises Price Target on Regeneron Pharmaceuticals to $766 From $708, Keeps Sector Perform Rating
|
MT
| |
07/01 |
BofA Securities Upgrades Regeneron Pharmaceuticals to Buy From Underperform, Raises Price Target to $860 From $627
|
MT
| |
07/01 |
Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says
|
MT
| |
03/01 |
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
|
GL
| |
01/01 |
US FDA declines to approve Outlook's eye disease drug for second time in 2025
|
RE
| |
31/12 |
Biocon And Regeneron Enter Global Settlement On Aflibercept Biosimilar
|
AQ
| |
29/12 |
Founder-CEOs: a driver of stock outperformance
|  | |
26/12 |
Johnson & Johnson halts mid-stage trial of experimental eczema drug
|
RE
| |
24/12 |
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic
|
AQ
| |
24/12 |
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update
|
DJ
| |
23/12 |
Sanofi, Regeneron Say Bronchial Asthma Treatment Approved in Japan for Children
|
MT
| |
23/12 |
Sanofi, Regeneron's Dupixent Wins Expanded Japanese Approval for Bronchial Asthma
|
MT
| |
23/12 |
Sanofi and Regeneron's Dupixent approved in Japan for children with bronchial asthma
|
RE
| |
23/12 |
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
|
GL
| |
23/12 |
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
|
CI
| |
23/12 |
Vyriad, Inc. announced that it has received $85 million in funding from Regeneron Pharmaceuticals, Inc., Mayo Clinic Ventures, Mirae Asset Venture Investment Co., Ltd., Southeast Minnesota Capital Fund LLC, Stine Seed Farm, Inc. and other investors
|
CI
| |
23/12 |
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
|
GL
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
